Global Task Force on Radiotherapy for Cancer Control

David A. Jaffray; Felicia M. Knaul; Rifat Atun; Cary Adams; Michael B. Barton; Michael Baumann; Yolande Lievens; Tracey Y.M. Lui; Danielle L. Rodin; Eduardo Rosenblatt; Julie Torode; Jacob van Dyk; Bhadrasain Vikram; Mary Gospodarowicz

doi:10.1016/S1470-2045(15)00285-5

Global Task Force on Radiotherapy for Cancer Control

David A. Jaffray, Felicia M. Knaul, Rifat Atun, Cary Adams, Michael B. Barton, Michael Baumann, Yolande Lievens, Tracey Y.M. Lui, Danielle L. Rodin, Eduardo Rosenblatt, Julie Torode, Jacob van Dyk, Bhadrasain Vikram, Mary Gospodarowicz

Research output: Contribution to journal › Comment/debate › peer-review

35 Scopus citations

Original language	English (US)
Article number	237
Pages (from-to)	1144-1146
Number of pages	3
Journal	The lancet oncology
Volume	16
Issue number	10
DOIs	https://doi.org/10.1016/S1470-2045(15)00285-5
State	Published - Sep 1 2015
Externally published	Yes

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(15)00285-5

Cite this

@article{a196fd6443a34f5fb0eddfdda07846a2,

title = "Global Task Force on Radiotherapy for Cancer Control",

author = "Jaffray, {David A.} and Knaul, {Felicia M.} and Rifat Atun and Cary Adams and Barton, {Michael B.} and Michael Baumann and Yolande Lievens and Lui, {Tracey Y.M.} and Rodin, {Danielle L.} and Eduardo Rosenblatt and Julie Torode and {van Dyk}, Jacob and Bhadrasain Vikram and Mary Gospodarowicz",

note = "Funding Information: DAJ reports grants or sponsored research agreements from Raysearch Laboratories, Philips Medical Systems, Eletka, Varian Medical Systems, Siemens Medical, and IMRIS; presenter fees from the American Society for Radiation Oncology; and royalties from Modus Medical and Precision X-ray related to non-patentable inventions, outside the submitted work and holds pending patents (US 2013/026137 A1, US61/178 319, US61/157 738, and US2013/0113802 A1) and issued patients (7399977, US11/867998, and PCT/US2007/067847), as well as issued patents licensed to Elekta (8 039 790 [with royalties received], 20040234115, 20040096038, 20040218719, 7472765 [with royalties received], and 7 147 373 [with royalties received]) and iRT (US60/806842, PCT/CA2007/001209, and EP20070763872). FMK has received grants from GlaxoSmithKline, Pfizer, NADRO, Chinoin, Sanofi SA, Roche, Susan G Komen for the Cure, Fogarty International Center, the Pan-American Health Organization, WHO, and the International Development Research Center; and support from the National Institute of Public Health Mexico, Centro de Investigacion y Docencias Economicas Mexico, PISA, Celgene, and Grunenthal. She is director of the Secretariat of the Global Task Force on Expanded Access to Cancer Care and Control, a board member of the Union for International Cancer Control, and the founding President of T{\'o}matelo a Pecho. YL is President-elect of the European Society for Radiotherapy and Oncology, an unpaid position. JVD received travel support from the Canadian Organization of Medical Physicists to attend meetings related to the Commission. TYML's institution received funds from the Union for International Cancer Control to support her salary for time spent working on The Lancet Oncology Commission on Global Radiotherapy. MG is a member of the board of directors of IBA, which manufactures proton therapy equipment. RA, MB, ER, MBB, BV, CA, JT, and DLR declare no competing interests.",

year = "2015",

month = sep,

day = "1",

doi = "10.1016/S1470-2045(15)00285-5",

language = "English (US)",

volume = "16",

pages = "1144--1146",

journal = "The lancet oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "10",

}

TY - JOUR

T1 - Global Task Force on Radiotherapy for Cancer Control

AU - Jaffray, David A.

AU - Knaul, Felicia M.

AU - Atun, Rifat

AU - Adams, Cary

AU - Barton, Michael B.

AU - Baumann, Michael

AU - Lievens, Yolande

AU - Lui, Tracey Y.M.

AU - Rodin, Danielle L.

AU - Rosenblatt, Eduardo

AU - Torode, Julie

AU - van Dyk, Jacob

AU - Vikram, Bhadrasain

AU - Gospodarowicz, Mary

N1 - Funding Information: DAJ reports grants or sponsored research agreements from Raysearch Laboratories, Philips Medical Systems, Eletka, Varian Medical Systems, Siemens Medical, and IMRIS; presenter fees from the American Society for Radiation Oncology; and royalties from Modus Medical and Precision X-ray related to non-patentable inventions, outside the submitted work and holds pending patents (US 2013/026137 A1, US61/178 319, US61/157 738, and US2013/0113802 A1) and issued patients (7399977, US11/867998, and PCT/US2007/067847), as well as issued patents licensed to Elekta (8 039 790 [with royalties received], 20040234115, 20040096038, 20040218719, 7472765 [with royalties received], and 7 147 373 [with royalties received]) and iRT (US60/806842, PCT/CA2007/001209, and EP20070763872). FMK has received grants from GlaxoSmithKline, Pfizer, NADRO, Chinoin, Sanofi SA, Roche, Susan G Komen for the Cure, Fogarty International Center, the Pan-American Health Organization, WHO, and the International Development Research Center; and support from the National Institute of Public Health Mexico, Centro de Investigacion y Docencias Economicas Mexico, PISA, Celgene, and Grunenthal. She is director of the Secretariat of the Global Task Force on Expanded Access to Cancer Care and Control, a board member of the Union for International Cancer Control, and the founding President of Tómatelo a Pecho. YL is President-elect of the European Society for Radiotherapy and Oncology, an unpaid position. JVD received travel support from the Canadian Organization of Medical Physicists to attend meetings related to the Commission. TYML's institution received funds from the Union for International Cancer Control to support her salary for time spent working on The Lancet Oncology Commission on Global Radiotherapy. MG is a member of the board of directors of IBA, which manufactures proton therapy equipment. RA, MB, ER, MBB, BV, CA, JT, and DLR declare no competing interests.

PY - 2015/9/1

Y1 - 2015/9/1

UR - http://www.scopus.com/inward/record.url?scp=84942123914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942123914&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(15)00285-5

DO - 10.1016/S1470-2045(15)00285-5

M3 - Comment/debate

C2 - 26419349

AN - SCOPUS:84942123914

SN - 1470-2045

VL - 16

SP - 1144

EP - 1146

JO - The lancet oncology

JF - The lancet oncology

IS - 10

M1 - 237

ER -

Global Task Force on Radiotherapy for Cancer Control

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this